Intellia Therapeutics (NASDAQ:NTLA) Posts Quarterly Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) issued its earnings results on Monday. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11, FiscalAI reports. The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 55.63%. During the same period in the previous year, the firm earned ($1.10) EPS.

Intellia Therapeutics Stock Up 2.1%

Shares of NTLA stock traded up $0.29 during trading hours on Wednesday, hitting $14.28. 2,266,036 shares of the company were exchanged, compared to its average volume of 5,299,091. The firm has a market cap of $1.72 billion, a PE ratio of -4.04 and a beta of 1.93. Intellia Therapeutics has a 1 year low of $6.83 and a 1 year high of $28.25. The firm has a fifty day moving average of $13.67 and a 200 day moving average of $12.15.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Benjamin Edwards Inc. increased its holdings in shares of Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Intellia Therapeutics by 13.9% during the second quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock valued at $111,000 after purchasing an additional 1,443 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Intellia Therapeutics during the third quarter valued at $30,000. Advisory Services Network LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth about $33,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Intellia Therapeutics by 38.6% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,080 shares of the company’s stock worth $122,000 after acquiring an additional 1,970 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NTLA shares. Wall Street Zen upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Citizens Jmp boosted their target price on shares of Intellia Therapeutics from $28.00 to $30.00 and gave the company a “market outperform” rating in a research note on Tuesday, April 28th. reissued a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. William Blair raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, March 2nd. Finally, Wedbush reissued a “neutral” rating and issued a $12.00 target price on shares of Intellia Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Hold” and a consensus price target of $20.25.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.